<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="influenza A virus infection when compared to the DAA drug" exact="Zanamivir" post="(100%) in parallel (Cheung et al., 2017). Another two"/>
 <result pre="CC50/EC50. As shown in Fig.Â 1D, the antiviral effect of" exact="Leflunomide" post="is hardly detectable at the cell culture level (EC50"/>
 <result pre="Â± 67.69 SI 5.10 65.38 53.13 3.14 32.26 141.75 32.64" exact="Leflunomide" post="EC50 &amp;gt;25.00 â€&quot; â€&quot; â€&quot; â€&quot; â€&quot; 41.49 Â±"/>
 <result pre="stronger than Favipiravir (EC50 = 66.85 Î¼mol/L), whereas its pro-drug" exact="Leflunomide" post="showed less inhibition of EC50 = 41.49 Î¼mol/L. Additionally,"/>
 <result pre="of Remdesivir (EC50 = 0.77 Î¼mol/L, SI &amp;gt; 129.87) and" exact="Chloroquine" post="(EC50 = 1.13 Î¼mol/L, SI &amp;gt; 88.50) (Wang et"/>
 <result pre="had much greater EC50 and SI values (66.5-fold stronger than" exact="Chloroquine" post="in EC50) against SARS-CoV-2. To determine more carefully the"/>
 <result pre="data in Fig.Â 2B clearly showed that all DHODHi including" exact="Leflunomide" post="(200 Î¼mol/L), Teriflunomide (67 Î¼mol/L), Brequinar (10 Î¼mol/L), S312"/>
 <result pre="dose of 5 mg/kg in the following experiments. FigureÂ 3" exact="Thein" post="vivoantiviral activity of S312 in influenza A virus-infected mice."/>
 <result pre="influenza and COVID-19, always induce pathogenic immunity as cytokine/chemokine storms." exact="Leflunomide" post="and Teriflunomide are already clinically used in autoimmune disease"/>
 <result pre="al., 2009; Gao et al., 2013; Hung et al., 2013)." exact="Leflunomide" post="and its active metabolite Teriflunomide have been approved for"/>
 <result pre="exist in COVID-19 patients. The active metabolite A771726 (Teriflunomide) of" exact="Leflunomide" post="inhibited the proliferation of PHA mitogen-stimulated human lymphocytes with"/>
 <result pre="46 Âµmol/L (Fox et al., 1999). The recommended dosage of" exact="Leflunomide" post="in treating rheumatoid arthritis (RA) is loading 100 mg/day"/>
 <result pre="0.05; EC50 = 6.00 Î¼mol/L at MOI = 0.03). As" exact="Leflunomide" post="has been widely used and proved to treat RA"/>
 <result pre="of data qualityActa Crystallogr Sect D200662728216369096 FoxRIHerrmannMLFrangouCGWahlGMMorrisREStrandVKirschbaumBJMechanism of action for" exact="leflunomide" post="in rheumatoid arthritisClin Immunol19999319820810600330 GaoGFFrom â€œAâ€�IV to â€œZâ€�IKV: attacks"/>
 <result pre="J200636316945126 MatsuokaYLamirandeEWSubbaraoKThe mouse model for influenzaCurr Protoc Microbiol20091315G-3 McNichollIRMcNichollJJNeuraminidase inhibitors:" exact="zanamivir" post="and oseltamivirAnn Pharmacother200135577011197587 Mei-jiaoGShi-fangLYan-yanCJun-junSYue-fengSTing-tingRYong-guangZHui-yunCAntiviral effects of selected IMPDH and"/>
 <result pre="virus through suppression of host pyrimidine biosynthesisJ Virol2011856548655621507975 WangMCaoRZhangLYangXLiuJXuMShiZHuZZhongWXiaoGRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
</results>
